Maximising therapeutic outcomes in patients failing on current therapy

Journal of the Neurological Sciences

Volumn 277, Issue SUPPL. 1, 2009, Pages

  Caon, Christina ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glatiramer acetate; Interferon beta; Multiple sclerosis; Observational studies; Switching; Treatment failure

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ALGORITHM; CLINICAL TRIAL; DEPRESSION; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; WEAKNESS;

EID: 59249087171     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)70010-3     Document Type: Editorial

References (9)

1. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol 255 Suppl 1 (2008) 37-43
2. Filippi M., Bozzali M., Rovaris M., Gonen O., Kesavadas C., Ghezzi A., et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126 (2003) 433-437
3. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., and Br̈uck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (2002) 2202-2212
4. Cohen B.A., Khan O., Jeffery D.R., Bashir K., Rizvi S.A., Fox E.J., et al. Identifying and treating patients with suboptimal responses. Neurology 63 (2004) S33-S40
5. Caon C., Din M., Ching W., Tselis A., Lisak R., and Khan O. Clinical course after change of immunomodulating therapy in relapsing remitting multiple sclerosis. Eur J Neurol 13 (2006) 471-474
6. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
7. Zwibel H.L. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 113 (2006) 378-386
8. Carrá A., Onaha P., Luetic G., Burgos M., Crespo E., Deri N., et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing remitting multiple sclerosis in Argentina. Eur J Neurol 15 (2008) 386-393
9. CMSC. Optimizing immunomodulatory therapy for MS patients. Int J MS Care Suppl (2002) 1-7